Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study (Q34479719)

2 August 2017

title

Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study (English)

1 reference

2 August 2017

Boris Gabriel

1

1 reference

2 August 2017

Dagmar-C Fischer

2

1 reference

2 August 2017

M Orlowska-Volk

3

1 reference

2 August 2017

Axel zur Hausen

4

1 reference

2 August 2017

Roland Schüle

5

1 reference

2 August 2017

Judith M Müller

6

1 reference

2 August 2017

Annette Hasenburg

7

1 reference

2 August 2017

publication date

1 January 2006

1 reference

2 August 2017

published in

Reproductive Sciences

1 reference

2 August 2017

volume

13

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

69-75

1 reference

Global cancer statistics, 2002

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Testosterone effects on the breast: implications for testosterone therapy for women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREM

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Characterization of the interaction between androgen receptor and a new transcriptional inhibitor, SHP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

FHL2, a novel tissue-specific coactivator of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Pharmacology of nuclear receptor-coregulator recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

The LIM domain: regulation by association

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

The LIM domain: from the cytoskeleton to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kappaB activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

BRCA1 interacts with FHL2 and enhances FHL2 transactivation function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.JSGI.2005.10.001

10.1016/J.JSGI.2005.10.001

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference